HR+ HER2-

What's new / Latest updates

07/01/2026 v1.2
Ribociclib added as a treatment option for high risk disease as per SMC 2803. Risk versus benefit statement updated and endocrine therapy advice added to CDK4/6 inhibitor box.

Throughout the patient pathway, consideration should be given to patient eligibility and suitability for available clinical trials and discussed with individual patients as appropriate.

Author	Pete Hall and Judy Fraser (on behalf of SACT subgroup)	Reviewer	Frances Yuille
Date of creation/update	Created 20/09/2023 Updated 07/01/2026	Version number	1.2
Description of last update	Ribociclib added as a treatment option for high-risk disease as per SMC 2803. Risk versus benefit statement updated and endocrine therapy advice added to CDK4/6 inhibitor box.
Review date	20/09/2026	nss.scottishcancernetwork@nhs.scot

The printing of visual pathways is strongly discouraged, due to the inability to print all relevant information contained within and behind the pathways. Any user choosing to do so must acknowledge that the information may be incomplete and that essential context may be missing from a printed or reproduced pathway.

SHTG Recommendation: The use of tumour profiling tests is recommended for patients who have an intermediate risk of distant recurrence, defined using a validated tool such as PREDICT or the NPI. Use is unlikely to provide additional benefit for decision making about adjuvant chemotherapy for patients with low or high clinical risk of distant recurrence.

HR+ HER2- Adjuvant

HR+ HER2- Neoadjuvant